ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

HGEN Humanigen Inc

0.0361
0.00 (0.00%)
May 02 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.0356
Ask Price 0.0358
News -
Day High

Low
0.0358

52 Week Range

High
0.207

Day Low
Share Name Share Symbol Market Stock Type
Humanigen Inc HGEN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.0361 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.0361 0.0361
Trades Shares Traded Average Volume 52 Week Range
0 0 - 0.0358 - 0.207
Last Trade Type Quantity Price Currency
- 0 US$ 0.0361 USD

Humanigen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 4.30M - - - -6.08
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Humanigen News

Date Time Source News Article
1/08/202416:02Edgar (US Regulatory)Form 8-K - Current report
9/14/202315:01Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No HGEN Message Board. Create One! See More Posts on HGEN Message Board See More Message Board Posts

Historical HGEN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.15380.2070.03580.0924193,746,622-0.1177-76.53%
3 Years19.3023.530.03582.323,184,600-19.26-99.81%
5 Years10.8529.200.03584.272,839,591-10.81-99.67%

Humanigen Description

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Your Recent History

Delayed Upgrade Clock